Seattle – September 24, 2026 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that President and CEO Steven Quay, M.D., Ph.D., will serve as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), scheduled for October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston.
Quay joins regulatory and academic leaders to discuss clinical pathways for aging-related diseases
The panel, titled "Clinical Trials in Diseases of Aging: From Evidence to New Therapeutics and Regulatory Pathways," is set for Thursday, October 1, 2026, from 11:20 a.m. to 12:00 p.m. ET. The session will be moderated by Sebastien Thuault, Editor at Nature Medicine, and will include Jill Lee, Director of Regulatory Policy & Intelligence at Novo Nordisk; Calum MacRae, Professor at Mass General Brigham; and Steve Horvath, Professor at UCLA.
Discussion targets translation of aging biology into clinical trial design and regulatory strategy
The panel will address how scientific evidence on aging and age-related diseases can be converted into clinical development programs, covering trial design, therapeutic development, and regulatory considerations for advancing treatments to patients.
Quay stated that clinical trials must be grounded in strong biological evidence, use measurable endpoints, and be designed with a clear regulatory pathway. He noted these considerations are directly relevant as Atossa expands its development efforts in rare diseases.
ARDD 2026 gathers global industry, academic and clinical stakeholders in longevity research
ARDD convenes leaders from pharmaceutical and biotechnology companies, academia, and clinical medicine to discuss advances in aging research and the translation of scientific discoveries into new medicines. The 2026 program covers clinical trials, regulatory pathways, drug discovery, emerging technologies, and approaches to extending healthy longevity.
Atossa's lead candidate, (Z)-endoxifen, a Selective Estrogen Receptor Modulator/Degrader, is currently in clinical development across multiple settings, including oncology and rare disease applications. The compound is not approved for any indication.